IP Library › Granted Patent US 10,894,989
Granted Patent B2
US 10,894,989 · App. 16/415,472 · Granted Jan 19, 2021

Treatment of angiogenesis disorders

Inventors: Sohail Tavazoie (New York, NY); Nils Halberg (Brooklyn, NY); Kim Png (New York, NY)
Assignee: The Rockefeller University
C12Q1/6886A61K38/1709A61K39/3955A61K45/06C07K16/18C12N15/113C12N15/1135A61K2039/505A61K2300/00C07K2317/73C07K2317/76C12N2310/113C12N2310/141C12N2320/11C12N2320/12C12N2330/31C12Q2600/106C12Q2600/118C12Q2600/136C12Q2600/158C12Q2600/16C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,894,989
App. No.
16/415,472
Granted
Jan 19, 2021
Kind
B2
Abstract

This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.

Claims (9)

1. A method for identifying a gene that regulates metastatic cancer colonization of a body tissue, comprising

a) introducing one or more DNA molecules that encode a protein into a population of starting cancer cells to generate a population of engineered cancer cells, the population of starting cancer cells being obtained according to a process comprising performing serial rounds of transplantation, isolation, and repeat transplantation of a population of labeled or unlabeled cancer cells into a living tissue;

b) transplanting said population of engineered cancer cells into a tissue of the body;

c) isolating transplanted cells to obtain a population of isolated cancer cells; and

d) assessing the quantity of the protein or of a nucleic acid encoding the protein in the population of isolated cancer cells,

wherein an increase in the quantity of said protein or of the nucleic acid in the population of isolated cells relative to its quantity prior to transplantation indicates that the protein is required for metastatic colonization of said tissue.

2. The method of claim 1 , wherein the assessing step is performed using microarray analysis, DNA sequencing technology, deep sequencing technology, or cloning analysis.

3. The method of claim 1 , wherein the assessing step is performed using one selected from the group consisting of enzyme-linked immunosorbent assay (ELISA), immuno-precipitations, immunofluorescence, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blotting analysis, and imaging techniques.

4. The method of claim 1 , wherein the nucleic acid comprises mRNA or cDNA.

Continuity (6)
Division 15629971 · Jun 22, 2017
Continuation 15350770 · Nov 14, 2016
Continuation 14658927 · Mar 16, 2015
Division 13984760
Provisional Application 61441738 · Feb 11, 2011
Related Publication 20190352722A1 · Nov 21, 2019